5402222025-07-012025-09-305402222025-09-305402222025-03-315402222025-04-012025-09-305402222025-07-012025-09-30in-capmkt:OtherExpenses1Member5402222025-04-012025-09-30in-capmkt:OtherExpenses1Member5402222025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15402222025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25402222025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss35402222025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15402222025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25402222025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss35402222025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15402222025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares540222LAURUSLABSNOTLISTEDINE947Q01028LAURUS LABS LIMITEDMain BoardEquity2025-04-012026-03-312025-10-232025-10-09INRCroresQuarterlySecond quarterSingle segmentManufacturer of Generics API, Generics FDF, Synthesis and Bio Technology2025-10-2314:00:002025-10-2314:55:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated16534700000269600000168043000006767500000307000000-44010000021556000004000000001204900000371210000014107000000269730000002697300000879100000-1193000007598000000193750000000074000001944900000-5670000018882000001949700000-48000001893000000-4800000107960000023.613.61003.613.611 The above consolidated unaudited financial results of Laurus Labs Limited ("the Company") including its subsidiaries (Collectively known as "the Group"), and its associates and joint venture (as mentioned in note 3) has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 23, 2025. The statutory auditors of the Company have carried out a limited review on consolidated financial results and have issued an unmodified conclusion in respect of the limited review for the quarter and six months ended September 30, 2025. <BR> 2 These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India <BR> 3 The consolidated financials include the results of the following entities <BR> Please see table in the results pdf <BR> 4 a The Company incorporated wholly owned subsidiary, Laurus Specialty Chemicals Private Limited in India on December 01, 2022. LSCPL has not commenced its operations. <BR> b During the quarter ended June 30, 2025, the company has invested Rs 40 Crores into Laurus Bio Private Limited as per the definitive agreement with Laurus Labs Limited (Parent Company), Eight Roads Ventures and F Prime Capital Investors <BR> c Pursuant to the joint venture agreement entered into by the Company with KRKA Pharma Private Limited KRKA, Capital contribution have been made into KRKA interms of the aforesaid agreement during the quarter ended December 31, 2024 for 49 percent stake. The Company has accounted for the investment in KRKA as joint venture w.e.f. October 03, 2024. <BR> 5 Pursuant to investment agreement entered into by the Company with Kurnool Renewables Private Limited, capital contributions have been made into Kurnool Renewables in terms of the aforesaid agreement during the quarter ended June 30, 2025 . The Company has accounted for its investment in Kurnool Renewables as an associate w.e.f May 12, 2025. <BR> 6 The Group is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108 Operating Segments <BR> 7 The Board of Directors of the Company, in its meeting held on August 21, 2025, approved the proposed Composite Scheme of Arrangement for the demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with the Company, subject to the necessary approval from National Company Law Tribunal, Amaravathi under section 230 and 232 of the Companies Act, 2013 and other applicable provisions of the Act and the rules made thereunder. The Company has filed a petition with NCLT on October 11, 2025. Upon approval of the Scheme, Laurus Synthesis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01, 2026 or such other date as the NCLT may approve. Pending such approval, the consolidated financial results of the Company for the quarter and six months ended September 30, 2025, quarter ended June 30, 2025, quarter and six months ended September 30, 2024 and year ended March 31, 2025 are presented without giving effect to the said merger. <BR> 8 During the quarter ended June 30, 2025, the Company allotted 572,408 equity shares of Rs 2 each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme. <BR> 9 The Board of Directors, at their meeting held on October 23, 2025 approved for the payment of interim dividend of Rs 0.80 per equity share of Rs 2 each2025-04-012025-09-30UnauditedConsolidated322304000003739000003260430000012761600000692000000-445700000430360000091500000023733000007065000000276648000004939500000049395000001479300000-88100000139120000003548300000000134000003561700000-6380000034979000003579900000-182000003516100000-18200000107960000026.636.63006.636.63Other Expenses3712100000Other Expenses7065000000380023000005408100000024630000001773000000002613200000004642000003077400000725000003036900000522375000002020960000001859440000049770000013610000015300000634000001930690000002398500000419150000000094152500000107960000046974300000480539000001281400000493353000005387700000000542600000593030000011282000002502000000575670000013065400000161058000004038000009739800000101436000002894200000291436000001207500000309700000109100000003175180000044817200000941525000000-8602000001247400000000-22050000000591400000000237330000002538100000000-1926000000483000005410000044100000000005526800000104663000000-88660000009425000005209000001093130000000000907000000029700000488910000001765000000000000000000000483000000310600000-4767700000001895000000000043760000059044000006410000043140000090680000000-6679600000-51600000018300000-497700000995400000497700000(i) Remeasurement gains/(losses) on defined benefit plans-2600000ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods700000iii) Share in other comprehensive income of the associates and joint ventures, nert of tax-100000-2000000(i) Remeasurement gains/(losses) on defined benefit plans-5100000ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods1300000iii) Share in other comprehensive income of the associates and joint ventures, nert of tax-100000-390000000Exchange differences on translating the financial statements of foreign operations-54700000-54700000Exchange differences on translating the financial statements of foreign operations-59900000-5990000000-56700000-63800000